NeuroOne to Host Investor Webinar Following Recent FDA Clearance

NeuroOne Medical Technologies Corporation announced it will conduct a virtual roadshow webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time to discuss its business operations, recent FDA clearance, and corporate updates. The webinar represents a significant opportunity for investors to gain insight into the company's progress following regulatory approval, which could substantially impact its commercial trajectory and market position in the neurological medical technology sector.

The event will feature a presentation followed by a question-and-answer session, accessible via webcast or dial-in numbers. Participants can join using U.S. toll-free number 888-506-0062 or international number 973-528-0011 with access code 619723. The webcast will also be available through the NMTC Virtual Webinar Link. A playback of the call will be available through October 21, 2025, by calling 877-481-4010 within the United States or 919-882-2331 internationally using replay passcode 53045.

This investor engagement comes at a critical juncture for NeuroOne as the company advances its minimally invasive and high-definition solutions for neurological disorders. The recent FDA clearance represents a major regulatory milestone that could accelerate the commercialization of technologies targeting epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain from failed back surgeries. These developments have significant implications for both patient care and healthcare economics, as NeuroOne's technologies aim to improve surgical outcomes while potentially reducing procedural costs.

The timing of this webinar underscores the company's transition from development to commercialization phase, making investor communication particularly important for market understanding and valuation. NeuroOne's focus on expanding applications to include depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence integration suggests substantial growth potential beyond its current neurological focus. For more information about the company's broader initiatives, investors can visit nmtc1.com.

The virtual format of this investor event reflects evolving corporate communication strategies in the post-pandemic era, allowing broader participation while maintaining regulatory compliance. As medical technology companies increasingly rely on digital engagement, NeuroOne's approach demonstrates adaptability in investor relations while addressing the complex regulatory landscape of neurological device development. The combination of recent regulatory progress and comprehensive business updates positions this webinar as a key event for understanding the company's strategic direction and market potential in the competitive medical technology space.